Dimensional Fund Advisors
KALV

Dimensional Fund Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Dimensional Fund Advisors’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-45,444
Closed -$554K – 3282
2025
Q3 		$554K Sell
45,444
-127,765
-74% -$1.77M ﹤0.01% 2979
2025
Q2 		$1.96M Sell
173,209
-472,784
-73% -$5.78M ﹤0.01% 2765
2025
Q1 		$7.46M Sell
645,993
-50,044
-7% -$511K ﹤0.01% 2369
2024
Q4 		$5.9M Buy
696,037
+89,001
+15% +$922K ﹤0.01% 2489
2024
Q3 		$7.03M Buy
607,036
+72,057
+13% +$906K ﹤0.01% 2417
2024
Q2 		$6.3M Sell
534,979
-44,680
-8% -$521K ﹤0.01% 2412
2024
Q1 		$6.87M Sell
579,659
-137,305
-19% -$1.83M ﹤0.01% 2461
2023
Q4 		$8.78M Buy
716,964
+134,059
+23% +$1.22M ﹤0.01% 2370
2023
Q3 		$5.61M Buy
582,905
+162,369
+39% +$1.66M ﹤0.01% 2496
2023
Q2 		$3.78M Buy
420,536
+184,269
+78% +$1.7M ﹤0.01% 2608
2023
Q1 		$1.86M Sell
236,267
-27,600
-10% -$206K ﹤0.01% 2760
2022
Q4 		$1.78K Sell
263,867
-72,251
-21% -$387K ﹤0.01% 2752
2022
Q3 		$4.88M Buy
336,118
+71,640
+27% +$1M ﹤0.01% 2434
2022
Q2 		$2.6M Buy
264,478
+188,926
+250% +$2.08M ﹤0.01% 2660
2022
Q1 		$1.11M Sell
75,552
-92,779
-55% -$1.33M ﹤0.01% 2968
2021
Q4 		$2.23M Sell
168,331
-1,877
-1% -$29.9K ﹤0.01% 2827
2021
Q3 		$2.97M Hold
170,208
– – ﹤0.01% 2733
2021
Q2 		$4.08M Sell
170,208
-58,417
-26% -$1.53M ﹤0.01% 2665
2021
Q1 		$5.87M Buy
228,625
+22,108
+11% +$581K ﹤0.01% 2520
2020
Q4 		$3.92M Buy
206,517
+10,336
+5% +$177K ﹤0.01% 2605
2020
Q3 		$2.47M Buy
196,181
+2,000
+1% +$25K ﹤0.01% 2684
2020
Q2 		$2.35M Buy
194,181
+25,339
+15% +$269K ﹤0.01% 2711
2020
Q1 		$1.29M Buy
168,842
+48,034
+40% +$648K ﹤0.01% 2834
2019
Q4 		$2.15M Sell
120,808
-7,682
-6% -$100K ﹤0.01% 2838
2019
Q3 		$1.49M Buy
128,490
+16,860
+15% +$272K ﹤0.01% 2928
2019
Q2 		$2.47M Buy
111,630
+39,083
+54% +$917K ﹤0.01% 2845
2019
Q1 		$2.08M Buy
72,547
+61,414
+552% +$1.33M ﹤0.01% 2888
2018
Q4 		$220K Sell
11,133
-1,250
-10% -$25.1K ﹤0.01% 3272
2018
Q3 		$274K Buy
+12,383
New +$167K ﹤0.01% 3268

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Dimensional Fund Advisors's KALV Position: Q4 2025 in Review

Dimensional Fund Advisors sold out of KalVista Pharmaceuticals (KALV) in Q4 2025, closing a stake of 45,444 shares — an estimated $554K sold.

Dimensional Fund Advisors first reported a position in KALV in Q3 2018 and held it in 29 quarters. The position peaked at $8.78M in Q4 2023. 161 funds tracked by Wall St. Rank hold KALV as of Q4 2025.

  • Dimensional Fund Advisors reported no remaining KalVista Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Dimensional Fund Advisors sold 45,444 KalVista Pharmaceuticals shares in Q4 2025, an estimated $554K.
  • Dimensional Fund Advisors first reported a position in KalVista Pharmaceuticals in Q3 2018 and held it in 29 quarters.
  • Dimensional Fund Advisors's KalVista Pharmaceuticals position peaked at $8.78M in Q4 2023.
  • 161 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2025.

Based on Dimensional Fund Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.